Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung.

A robust immunohistochemical (IHC) assay for VEGFR2 was developed to investigate its utility for patient tailoring in clinical trials. The sensitivity, specificity, and selectivity of the IHC assay were established by siRNA knockdown, immunoblotting, mass spectrometry, and pre-absorption experiments...

Full description

Bibliographic Details
Main Authors: Timothy R Holzer, Angie D Fulford, Drew M Nedderman, Tara S Umberger, Rebecca R Hozak, Adarsh Joshi, Symantha A Melemed, Laura E Benjamin, Gregory D Plowman, Andrew E Schade, Bradley L Ackermann, Robert J Konrad, Aejaz Nasir
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3828187?pdf=render